SCHEMBL24979407

SCHEMBL24979407

CC(C)C(=O)CCNC(=O)CCN1C(=O)CC(C(C)C)C1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
POLB P06746 2/20 0.35
HSD17B10 Q99714 1/20 0.35
ALDH1A1 P00352 6/20 0.34
GAA P10253 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33
CYP2C19 P33261 5/20 0.33
CYP3A4 P08684 4/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29328305 0.89 HDAC3 (0.38) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL18466109 0.89 HDAC6 (0.39) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL24658573 0.89 SMN1; SMN2 (0.37) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL11916135 0.88 SMN1; SMN2 (0.36) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL16867169 0.87 HDAC3 (0.39) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL16867171 0.87 HDAC3 (0.39) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL278538 0.87 POLB (0.34) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL29322783 0.86 HDAC3 (0.37) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL18557292 0.86 LMNA (0.43) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL18557291 0.85 MEN1 (0.46) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226313-A1 CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF SEAGEN INC. 2024-07-11 US disclosed
US-20240226313-A1 CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF SEAGEN INC. 2024-07-11 US disclosed
US-20230036256-A1 CAMPTOTHECIN CONJUGATES SEAGEN INC. 2023-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226313-A1 CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF EPCAM, TOP2A, SPAG5 HDAC3 2516/4885HDAC4 1447/4885HDAC1 1887/4885
US-20230036256-A1 CAMPTOTHECIN CONJUGATES DCLRE1A, TOP2A, PAICS HDAC3 4131/4885HDAC4 3533/4885HDAC1 3609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.